Trial Profile

An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination With Ruxolitinib in Patients With Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RVU 120 (Primary) ; Ruxolitinib
Indications Myelofibrosis
Focus Therapeutic Use
Acronyms POTAMI-61
Sponsors Ryvu Therapeutics

Most Recent Events

03 Nov 2025 Results published in the Media Release
03 Nov 2025 According to Ryvu Therapeutics media release, company will present data from preliminary results from POTAMI-61, at the 2025 American Society of Hematology (ASH) Annual Meeting, 2025 December 6, 5:30-7:30 PM EST, in Orlando, Florida.
12 Jun 2025 According to Ryvu Therapeutics media release, The full week 24 data are anticipated in Q4 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com